Literature DB >> 10476790

Risk factors for late presentation in chronic glaucoma.

S Fraser1, C Bunce, R Wormald.   

Abstract

PURPOSE: To identify the risk factors for having advanced glaucomatous visual field loss on the first visit at three hospital eye services.
METHODS: This was a hospital-based, case-control study involving patients newly diagnosed with glaucoma at first visit to one of three ophthalmic departments in the United Kingdom. Patients with a previous history of ocular hypertension or any documented suspicion of glaucoma (within the hospital eye service) were excluded.
RESULTS: Occupational group, initial intraocular pressure (IOP), family history of glaucoma, method of referral to hospital, and the number of years since the last visit to an optometrist were found to be independently associated with late presentation. A linear trend of increasing odds of late attendance was associated with increasing Standard Occupational Classification. Those in managerial (category II) and skilled (category III) groups estimated (95% confidence intervals) to be, respectively. 0.2 (0.00, 0.16) and 0.27 (0.1, 0.8) as likely to attend with advanced glaucomatous field loss as unskilled (category V) people with similar initial IOP, family history, referral route, and time since last optometrist visit. The data strongly suggest an association between IOP and advanced field loss at initial hospital examination. There was a 1.2 (1.12, 1.28) increase in the OR of late presentation per unit increase in millimeters of mercury after adjustment for the other mentioned factors. People with a family history of glaucoma were estimated to be almost one third (adjusted OR, 0.29 [0.12, 0.74]) as likely to have advanced field loss as those with no family history. People referred by any source other than an optometrist who has made the correct diagnosis of glaucoma were 4.5 times (adjusted OR, 4.53 [1.52, 13.48]) more likely to be late attenders than patients so referred but similar in other mentioned factors. These data also provide strong evidence that the more years since the last visit to an optometrist, the greater the likelihood of having advanced glaucomatous visual field loss on the first visit to the eye service (adjusted OR per year, 1.25 [1.10, 1.42]).
CONCLUSIONS: These data strongly suggest that certain subgroups of people with glaucoma were at greater risk of having advanced and irremediable field loss on first visiting the eye services studied.

Entities:  

Mesh:

Year:  1999        PMID: 10476790

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  Glaucoma Care of Prison Inmates at an Academic Hospital.

Authors:  Levi N Kanu; Inae Jang; Daniel J Oh; Manpreet S Tiwana; Amy A Mehta; Mark S Dikopf; Thasarat S Vajaranant; Ahmad A Aref; Deepak P Edward
Journal:  JAMA Ophthalmol       Date:  2020-04-01       Impact factor: 7.389

2.  Deprivation and late presentation of glaucoma: case-control study.

Authors:  S Fraser; C Bunce; R Wormald; E Brunner
Journal:  BMJ       Date:  2001-03-17

3.  Visual field-based grading of disease severity in newly diagnosed primary open angle glaucoma patients presenting to a tertiary eye care centre in India.

Authors:  Sharmila Rajendrababu; Oshin Bansal; Sujani Shroff; Vijayalakshmi A Senthilkumar; Mohammed Sithiq Uduman
Journal:  Int Ophthalmol       Date:  2021-05-09       Impact factor: 2.031

4.  Severity of Visual Field Loss at First Presentation to Glaucoma Clinics in England and Tanzania.

Authors:  Pete R Jones; Heiko Philippin; William U Makupa; Matthew J Burton; David P Crabb
Journal:  Ophthalmic Epidemiol       Date:  2019-09-13       Impact factor: 1.648

5.  Awareness of glaucoma, and health beliefs of patients suffering primary acute angle closure.

Authors:  S-M Saw; G Gazzard; D Friedman; P J Foster; J G Devereux; M L Wong; S Seah
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

6.  The accuracy of accredited glaucoma optometrists in the diagnosis and treatment recommendation for glaucoma.

Authors:  A Azuara-Blanco; J Burr; R Thomas; G Maclennan; S McPherson
Journal:  Br J Ophthalmol       Date:  2007-05-30       Impact factor: 4.638

7.  Glaucoma Awareness and Self-Care Practices among the Health Professionals in a Medical College Hospital.

Authors:  Nimitha Nageeb; Uma D Kulkarni
Journal:  J Clin Diagn Res       Date:  2015-12-01

8.  Determinants of glaucoma awareness and knowledge in urban Chennai.

Authors:  Ramesh Ve Sathyamangalam; Pradeep G Paul; Ronnie George; Mani Baskaran; Arvind Hemamalini; Raj V Madan; J Augustian; Raju Prema; Vijaya Lingam
Journal:  Indian J Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 1.848

Review 9.  Advanced glaucoma at diagnosis: current perspectives.

Authors:  Alan Kastner; Anthony J King
Journal:  Eye (Lond)       Date:  2019-11-18       Impact factor: 3.775

10.  Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression.

Authors:  Jamie E Craig; Xikun Han; Ayub Qassim; Alex W Hewitt; Stuart MacGregor; Mark Hassall; Jessica N Cooke Bailey; Tyler G Kinzy; Anthony P Khawaja; Jiyuan An; Henry Marshall; Puya Gharahkhani; Robert P Igo; Stuart L Graham; Paul R Healey; Jue-Sheng Ong; Tiger Zhou; Owen Siggs; Matthew H Law; Emmanuelle Souzeau; Bronwyn Ridge; Pirro G Hysi; Kathryn P Burdon; Richard A Mills; John Landers; Jonathan B Ruddle; Ashish Agar; Anna Galanopoulos; Andrew J R White; Colin E Willoughby; Nicholas H Andrew; Stephen Best; Andrea L Vincent; Ivan Goldberg; Graham Radford-Smith; Nicholas G Martin; Grant W Montgomery; Veronique Vitart; Rene Hoehn; Robert Wojciechowski; Jost B Jonas; Tin Aung; Louis R Pasquale; Angela Jane Cree; Sobha Sivaprasad; Neeru A Vallabh; Ananth C Viswanathan; Francesca Pasutto; Jonathan L Haines; Caroline C W Klaver; Cornelia M van Duijn; Robert J Casson; Paul J Foster; Peng Tee Khaw; Christopher J Hammond; David A Mackey; Paul Mitchell; Andrew J Lotery; Janey L Wiggs
Journal:  Nat Genet       Date:  2020-01-20       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.